Hi all,

I got this through http://www.medicalnewstoday.com/articles/139659.php

You may have to sign on to Medical News Today as a subscriber to view the
original

I have heard of filtration of the blood before, one involved UV exposure of
the blood as it was drawn from the body and then recirculated without the
virons.  The reason for this procedure apparently is to lower the
concentration of the virus in the body and thereby promote the achievement
of a Rapid Viral Response (RVR) during conventional follow-up with
combination treatment with Interferon and Ribavirin.  This may be that
procedure, I don't know.  It involves blood dialysis.

- cactus jammies
____________________________________

Aethlon Medical Announces Completion Of 30-Day Hepatitis-C Treatment Study
Main Category: Liver Disease / Hepatitis
Article Date: 22 Feb 2009 - 0:00 PST

Aethlon Medical, Inc. (OTCBB:AEMD) announced that it has completed a 30-day
treatment case study to further evaluate the safety and efficacy of the
Aethlon Hemopurifier® as a candidate treatment for Hepatitis-C Virus (HCV)
infection. The Hemopurifier® is a first-in-class medical device that assists
the immune response in combating infectious disease through real-time
therapeutic filtration of infectious viruses and immunosuppressive proteins.
As in previous studies, which demonstrated robust viral load reductions
resulting from three Hemopurifier® treatments administered in a one-week
trial, the study enrolled an HCV patient suffering from end-stage renal
disease (ESRD) requiring regular kidney dialysis treatment. The study goal
was to further demonstrate the Aethlon Hemopurifier® inhibits the
progression of HCV in infected ESRD patients. The study protocol provided
for 12 Hemopurifier(R) treatments to be administered during the patient's
normally scheduled dialysis treatment. As a result, a 4-hour Hemopurifier®
treatment was administered thrice weekly over a period of 30 days. There
were no observed adverse events were reported in any of the treatments. The
study was conducted at the Fortis Hospital in Delhi, India. Aethlon will
disclose viral load and associated data upon receipt from testing
laboratories. The insight obtained from the study will help define future
clinical protocols and early commercialization strategies. The study data
may also be utilized to expand the scope of an IDE submission to the FDA to
include the potential use of the Hemopurifier® in the United States as a
device designed for the single-use removal of HCV from blood. At present,
the focus of Aethlon's IDE submission has been directed towards high risk
bioterror and emerging pandemic threats.

It is estimated that up to 20% of the 1.6 million global ESRD population is
infected with HCV. Beyond the treatment of infected ESRD patients, the
overall opportunity for the Hemopurifier® is HCV care is significant, as
approximately 180 million people worldwide (3% of the world's population)
are HCV infected. According to the World Health Organization (WHO), only
30-50% of infected patients will beneficially respond to the 48-week
pegylated interferon-ribavirin treatment standard.

"While we still have much work ahead, I am proud that our research and
clinical programs allow us the opportunity to expand the therapeutic
filtration industry beyond kidney dialysis and into the much larger
infectious disease and cancer markets," stated Aethlon Chairman and CEO, Jim
Joyce. "The continued demonstration of Hemopurifier® safety and
effectiveness increases the likelihood that our technology will be available
to extend and improve the lives of those suffering from these horrific
conditions," concluded Joyce.

In a previous studies conducted the Fortis Hospital, six ESRD patients
received a series of three, 4-hour Hemopurifier® treatments every other day
during the course of one week. The treatment regimen also mirrored the
patient's normal kidney dialysis schedule, allowing for the inclusion of the
Hemopurifier® without disrupting dialysis treatment. Robust viral load
reductions were observed in three HCV patients who completed the
three-treatment protocol. Patient #1 had a 95% reduction three days post
treatment and 89% reduction seven days post treatment. Patient #2 had a 85%
reduction three days post treatment and 50% reduction seven days post
treatment, and patient #3 had a 60% reduction three days post treatment and
83% reduction seven days post treatment.

Aethlon additionally disclosed that it soon expects the receipt of viral
load and blood chemistry data resulting from a recently completed 30-day HIV
treatment case study. The Hemopurifier® is the first medical device to
target the treatment of both HIV and HCV, as well as a broad-spectrum of
other infectious viral pathogens.

About Aethlon Medical

Aethlon Medical creates diagnostic and therapeutic filtration devices to
improve the health of individuals afflicted with infectious disease and
cancer. The Company's lead product, the Aethlon Hemopurifier®, is a
first-in-class artificial adjunct to the immune system proven to capture
infectious viruses and immunosuppressive particles from circulation. The
device targets to inhibit disease progression of Hepatitis-C Virus (HCV) and
Human Immunodeficiency Virus (HIV), and serves as a broad-spectrum treatment
countermeasure against bioterror and emerging pandemic threats. The
Hemopurifier® also holds promise in cancer care, as research studies verify
the Hemopurifier® effectively captures immunosuppressive exosomes that are
secreted by tumors to kill-off immune cells. At present, over sixty-five
(65) Hemopurifier® treatments (representing approximately 260 hours of
treatment time) have been conducted in multi-site studies at the Apollo
Hospital, Fortis Hospital, and Sigma New-Life Hospital in India. The studies
enrolled end-stage renal disease (ESRD) patients infected with either HCV or
HIV. In addition to establishing treatment safety, robust viral load
reductions have been reported in HCV-infected patients who completed a
three-treatment protocol during the course of one week.

Research studies have also demonstrated the Hemopurifier® is effective in
capturing a broad-spectrum of viruses untreatable with drug therapy,
including several of world's deadliest bioterror and pandemic threats. These
include: Dengue hemorrhagic fever (DHF), Ebola hemorrhagic fever (EHF),
Lassa hemorrhagic fever (LHF), H5N1 avian influenza (Bird Flu), the
reconstructed 1918 influenza virus (r1918), West Nile virus (WNV), and
Vaccinia and Monkeypox (MPV), which both serve as models for human smallpox
infection. The studies were conducted with the assistance of researchers
representing: The U.S. Army Medical Research Institute of Infectious
Diseases (USAMRIID); The Centers for Disease Control and Prevention (CDC);
The National Institute of Virology (NIV); The Battelle Biomedical Research
Center (BBRC); and The Southwest Foundation for Biomedical Research (SFBR).

In additional to therapeutic market opportunities, Aethlon is leveraging
principles underlying the Hemopurifier® technology platform to establish a
pipeline of clinical and research diagnostic products and services.
Additional information regarding Aethlon Medical can be accessed online at
http://www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks
and uncertainties. Such forward-looking statements involve assumptions,
known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of Aethlon Medical, Inc to be
materially different from any future results, performance, or achievements
expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the development
of its planned products, the ability of the Company to obtain FDA and other
regulatory approvals permitting the sale of its products, the Company's
ability to manufacture its products and provide its services, the impact of
government regulations, patent protection on the Company's proprietary
technology, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such
instances, actual results could differ materially as a result of a variety
of factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the Company's
Securities and Exchange Commission filings.

Aethlon Medical

- Cactus Jammies